News

Impressive returns might be easier to achieve the old-fashioned way.

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...

The stock is down, but it isn't out yet.

The Number Gold’s proxy in the equity market, SPDR Gold Shares (NYSEARCA:GLD), has returned 22.27% over the past twelve months, climbing from $309.25 on July 2, 2025 to $378.13 on July 2, 2026. That single figure, a full-year total return on the world’s most-watched safe-haven vehicle, is why sell-side desks are rebuilding their commodity assumptions ... A $1,000 Gold Rally? Why Analysts Are Repricing Safe Havens

Procter & Gamble and Progressive are among the stocks that could rise after reporting earnings, according to Citi strategist Scott Chronert.

Is its current momentum worth investors hopping on the train?

Figma (NYSE:FIG) was reinstated with a ‘Buy’ rating and a $30 price objective by Bank of America, with the firm arguing that artificial intelligence is likely to strengthen the company's competitive position rather than undermine it. Shares of Figma traded higher on the news, adding more than...

Meta has launched Muse Image, its debut AI-driven image generation model from Meta Superintelligence Labs, integrating multi-photo blending and intelligent layout planning into Meta AI.

SCHA's broader portfolio delivered stronger one-year returns, while SPSM offers a higher dividend yield and lower volatility.

Oil prices climbed higher after the U.S. government revoked sanction waivers for Iranian oil after commercial ship attacks. Brent crude futures climbed more than 5.1% to $75.65 per barrel while WTI futures rose 5% to $71.99. Oil prices were well below wartime highs, but still above prewar levels.

A 75 million share offering overshadows Q2 revenue guidance

Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index. The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters. Pfizer’s high yield reflects investors’ trepidation over the stock.

UBS expects SK Hynix's planned U.S. ADRs could trade at a premium to Seoul-listed shares.

The AI revolution is expanding beyond GPU chips, much to the benefit of these three stocks.

Dow Jones payments leader Visa stock is in a new buy zone, while Arista Networks shares are approaching their own entry.

MoffettNathanson is Wall Street's lone skeptic on SpaceX despite a wave of bullish IPO calls.

Chinese companies plan to raise domestic AI accelerator spending as Beijing advances its AI infrastructure strategy.

Index-inclusion day is supposed to be a party. Passive funds line up to buy, forced demand meets thin supply, and the newly added stock pops. That is the script. SpaceX (NASDAQ:SPCX) officially joined the Nasdaq 100 today, and by lunchtime shares were down 5.65% to $151.35, while the broader Nasdaq 100 proxy QQQ slipped 1.74%. ... $27 Billion Is About to Chase SpaceX Into the Nasdaq 100, and Smart Money Already Beat You to It

Shares of Super Micro Computer (NASDAQ:SMCI) are changing hands at $26 and change midday on Tuesday, capping a punishing stretch that has left the stock down 36% over the past month. The AI server maker has become the clear laggard of the datacenter hardware group, even as spending on AI infrastructure continues at a record ... Super Micro Just Collapsed 36% In a Month: Is It Time to Buy This Low-P/E Prospect?

MU, STX and SNX screened as top momentum stocks, combining strong price trends, earnings surprises and growth expectations for July.

VRT and QUBT stand out for exposure to AI infrastructure and quantum computing as hyperscale spending and U.S. policy support fuel 2026 momentum.

Record AI-driven memory earnings topped forecasts, yet investors sold after a near-150% rally this year.

Piper Sandler sees room for stronger growth as Oracle adds more cloud capacity.

US foreclosed home listings climbed to their highest level in six years as properties continued to h

Microsoft has begun routing Copilot queries in key Office apps away from external partners such as OpenAI and Anthropic to its proprietary models.

Shares of Vera Therapeutics rose about 8% Tuesday after the Food and Drug Administration approved its treatment for a kidney disease, IgA nephropathy, that affects about 160,000 people in the U.S. and often leads to kidney failure. The drug, called Trutakna, works by blocking two proteins that push the immune system to make antibodies that build up in the kidneys and cause damage. It is the first drug approved in the U.S. that targets both proteins at once, though several other drugs already treat the disease.

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Arbutus expects to receive around $179 million from Moderna.

While headlines focus on SpaceX's massive debt and losses, these four aerospace stocks offer a potentially more reliable way to profit from the industry's growth.

Alibaba Group Holding (NYSE:BABA) has initiated a substantial share repurchase program, authorizing the buyback of up to 1,907,598,428 shares, which represents 10% of its issued share capital as of September 2025. See our latest analysis for Alibaba Group Holding. Despite announcing the sizeable buyback and rolling out new AI and mapping products, Alibaba Group Holding’s recent share price momentum has been weak. The 30 day share price return is down 19.12%, and the year to date share price...